Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.51B 2.18B 2.04B 1.87B 3.54B 239B 3.57B 24B 9.38B 120B 9.44B 9.23B 396B P/E 2026 *
-135x
P/E 2027 * 36.8x
Enterprise Value 2.51B 2.18B 2.04B 1.87B 3.54B 239B 3.57B 24B 9.38B 120B 9.44B 9.23B 396B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 1.84x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day-5.98%
1 week-9.39%
Current month-3.09%
1 month-9.99%
3 months-11.06%
6 months-11.88%
Current year-12.98%
1 week 42.62
Extreme 42.625
52.5
1 month 42.62
Extreme 42.625
52.5
Current year 42.45
Extreme 42.45
59.68
1 year 38.26
Extreme 38.26
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
29/07/26 Free

Chief Financial Officer

1,250 0.0022%
29/07/26 Free

Founder

29,849 0.0532%
29/07/26 Free

Chief Technology Officer

750 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
-5.98%-9.39%+16.73%+34.40% 2.51B
+0.18%-2.90%+60.28%+21.90% 316B
+2.74%+1.46%+35.26%-9.44% 73.28B
+1.17%-0.26%+38.74%+96.25% 9.87B
-0.41%-9.67%-4.98%-8.27% 8.15B
+1.79%+0.38%-16.96%-17.13% 4.38B
+1.63%+5.80%-33.57%+6.86% 3.91B
+3.58%+0.05%-16.91%+18.28% 3.62B
-0.82%+6.62%-2.59%-3.15% 2.24B
-1.68%+1.86%-23.34%-15.75% 1.74B
Average +0.22%-0.07%+5.27%+12.40% 42.59B
Weighted average by Cap. +0.64%-1.98%+50.98%+16.88%

Financials

2026 *2027 *
Net sales 881M 765M 713M 655M 1.24B 83.83B 1.25B 8.41B 3.29B 41.9B 3.31B 3.24B 139B 1.37B 1.19B 1.11B 1.02B 1.93B 130B 1.95B 13.08B 5.11B 65.14B 5.14B 5.03B 216B
Net income -18.67M -16.21M -15.11M -13.88M -26.26M -1.78B -26.54M -178M -69.65M -888M -70.1M -68.56M -2.94B 68.56M 59.53M 55.5M 50.99M 96.43M 6.52B 97.49M 654M 256M 3.26B 257M 252M 10.8B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
04/08/26 US$43.25 -5.98% 3,705,542
03/08/26 US$46.00 +3.07% 4,518,516
31/07/26 US$44.63 -2.15% 573,626
30/07/26 US$45.61 -2.06% 468,740
29/07/26 US$46.57 -2.43% 522,131
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
43.25USD
Average target price
62.50USD
Spread / Average Target
+44.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock